Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Deep neural networks are superior to dermatologists in melanoma image classification.
Brinker TJ, Hekler A, Enk AH, Berking C, Haferkamp S, Hauschild A, Weichenthal M, Klode J, Schadendorf D, Holland-Letz T, von Kalle C, Fröhling S, Schilling B, Utikal JS. Brinker TJ, et al. Among authors: utikal js. Eur J Cancer. 2019 Sep;119:11-17. doi: 10.1016/j.ejca.2019.05.023. Epub 2019 Aug 8. Eur J Cancer. 2019. PMID: 31401469 Free article.
[90-year-old male with a hyperkeratotic lichenoid skin eruption].
Bauer U, Ugurel S, Utikal J, Schadendorf D, Goerdt S. Bauer U, et al. J Dtsch Dermatol Ges. 2005 Feb;3(2):137-9. doi: 10.1111/j.1610-0378.2005.04082.x. J Dtsch Dermatol Ges. 2005. PMID: 16351017 German. No abstract available.
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pföhler C, Schiller M, Hauschild A, Hein R, Kämpgen E, Kellner I, Leverkus M, Becker JC, Ströbel P, Schadendorf D. Ugurel S, et al. Clin Cancer Res. 2014 Jan 15;20(2):499-510. doi: 10.1158/1078-0432.CCR-13-1411. Epub 2013 Oct 30. Clin Cancer Res. 2014. PMID: 24173542 Clinical Trial.
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U, Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, Paschen A, Hillen U, Schadendorf D; DeCOG. Schilling B, et al. Ann Oncol. 2014 Mar;25(3):747-753. doi: 10.1093/annonc/mdt587. Epub 2014 Feb 6. Ann Oncol. 2014. PMID: 24504444 Free PMC article.
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.
Ugurel S, Loquai C, Kähler K, Hassel J, Berking C, Zimmer L, Haubitz I, Satzger I, Müller-Brenne T, Mikhaimer NC, Becker JC, Kilian KJ, Schadendorf D, Heinzerling L, Kaatz M, Utikal J, Göppner D, Pföhler C, Pflugfelder A, Mössner R, Gutzmer R; Dermatologic Cooperative Oncology Group (DeCOG). Ugurel S, et al. Ann Oncol. 2015 Mar;26(3):573-82. doi: 10.1093/annonc/mdu573. Epub 2014 Dec 18. Ann Oncol. 2015. PMID: 25524477 Free article.
Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study.
Livingstone E, Krajewski C, Eigentler TK, Windemuth-Kieselbach C, Benson S, Elsenbruch S, Hauschild A, Rompel R, Meiss F, Mauerer A, Kähler KC, Dippel E, Möllenhoff K, Kilian K, Mohr P, Utikal J, Schadendorf D. Livingstone E, et al. Eur J Cancer. 2015 Mar;51(5):653-67. doi: 10.1016/j.ejca.2015.01.007. Epub 2015 Jan 28. Eur J Cancer. 2015. PMID: 25638778
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E, Livingstone E, Bluhm L, Rompel R, Griewank KG, Fluck M, Schilling B, Schadendorf D. Zimmer L, et al. PLoS One. 2015 Mar 11;10(3):e0118564. doi: 10.1371/journal.pone.0118564. eCollection 2015. PLoS One. 2015. PMID: 25761109 Free PMC article. Clinical Trial.
339 results